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Abstract
A new paradigm in disease classification, diagnosis and treatment is rapidly approaching. Known as precision medicine,
this new healthcare model incorporates and integrates genetic information, microbiome data, and information on
patients’ environment and lifestyle to better identify and classify disease processes, and to provide custom-tailored
therapeutic solutions. In spite of its promises, precision medicine faces several challenges that need to be overcome to
successfully implement this new healthcare model. In this paper we identify four main areas that require attention: data,
tools and systems, regulations, and people. While there are important ongoing efforts for addressing the first three areas,
we argue that the human factor needs to be taken into consideration as well. In particular, we discuss several studies that
show how primary care physicians and clinicians in general feel underequipped to interpret genetic tests and direct-to-
consumer genomic tests. Considering the importance of genetic information for precision medicine applications, this is a
pressing issue that needs to be addressed. To increase the number of professionals with the necessary expertise to
correctly interpret the genomics profiles of their patients, we propose several strategies that involve medical curriculum
reforms, specialist training, and ongoing physician training.
Background
On January 20, 2015 as part of his State of the Union
Address, President Obama announced the Precision
Medicine Initiative, a program backed by $215 million
aimed at initiating a paradigm shift for modern medicine
[1]. The goal of this initiative is to create a more targeted
approach to disease prevention and treatment. Instead
of using generalized diagnostic protocols and treatment
options, the genetic make-up of each individual patient
and information about their lifestyle and environment
would be directly incorporated into diagnosis and treat-
ment recommendations. The funding would provide
$200 million in new spending to the National Institutes
of Health (NIH), $10 million for the Food and Drug
Administration (FDA), and the remaining $5 million
would go to the Office of the National Coordinator for
Health Information Technology (ONC) [2].
This multipronged approach is aiming to create the
foundation for building precision medicine. It also high-
lights four principal components that are needed for this
endeavor to succeed: (1) data, (2) tools and systems, (3)
regulation, and (4) people. The first component ad-
dresses the need for robust multifaceted biomedical data
sets. These data sets represent the knowledge base from
which information supporting precision medicine will be
drawn. For example, these data sets will enable quantita-
tive risk estimates for given disorders, help identify new
biological markers, and will be instrumental in pinpoint-
ing individual variation in responding to drug therapies
(pharmacogenomics). The second component involves
developing the tools needed to work with these complex
data sets. This component also includes building the
infrastructure and defining the interoperability rules of
the network where the data will be housed and
exchanged. The privacy, ethics, and regulatory structure
required for that network are included in the third
component. The final component is people, the key
stakeholders who will be using, building, and maintain-
ing the three previous components.
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Precision medicine
The concepts of precision medicine and its older sibling
term, personalized medicine, are not new [3, 4]. The
term “personalized medicine” has slightly fallen out of
favor due to the possibility of “personalized” being con-
fused with efforts to craft treatments and preventions
unique to each individual. The argument against the use
of the term “personalized medicine” is that the best
physicians have always treated their patients on an indi-
vidual, personalized level. In contrast, the term “preci-
sion medicine” seems to better capture the emphasis on
treating and preventing diseases based on genetic,
lifestyle-related, and environmental factors [5]. However,
the two terms are often still used interchangeably.
How to prepare for this new model of care has been
examined and discussed previously [6–8]; however, the
Precision Medicine Initiative represents the first formal
drive in the United States to integrate precision medi-
cine into healthcare and clinical practice. The U.S. is not
the first country to establish a major health initiative
aimed at building a massive database of genomic infor-
mation. Genomics England, a company owned by the
United Kingdom Department of Health, was established
in July 2013 to sequence the genome of 100,000 British
citizens, and has been provided £300 million to accom-
plish this task [9]. It appears efforts to bring precision
medicine to fruition are well on their way.
Another major healthcare change has existed in the
United States for several years, and its scope and size
diminish the Precision Medicine Initiative to the status
of a small start-up in comparison to the likes of Google
and Microsoft. This change is the Health Information
Technology for Economic and Clinical Health (HITECH)
Act, which was included in the American Recovery and
Reinvestment Act of 2009. HITECH provided the United
States Department of Health and Human Services with
$29.5 billion to encourage the adoption of Electronic
Health Records (EHRs) and to establish meaningful use
for interoperability [10].
The progress of the program has been mixed. From
2009–2013, the percentage of hospitals adopting an EHR
system with a basic set of EHR functions (including
clinician notes) grew from 12 % to 44 %. However, the
adoption of comprehensive.
EHRs only grew from 1.6 % to 16.9 % over the same
period [11]. Further, there was a disparity between where
adoption was occurring and physician satisfaction levels.
Small, nonteaching, and rural hospitals lagged behind
their larger peers in adopting EHRs [12], as did smaller
private practices and clinics [13]. In a survey conducted
by the American Medical Association, satisfaction with
EHRs dropped significantly over the past 5 years. In
2009, 61 % of respondents were satisfied or very satisfied
with their EHR systems; now only 34 % feel that way
[14]. Sites resisting EHR adoption often cite cost, prod-
uctivity loss, finding an EHR platform that meets the
practice’s needs, and training as their principal barriers
[15]. The experience with EHR expansion efforts in the
US should be used to guide efforts to integrate precision
medicine into healthcare. Despite the clinical promise
offered by EHRs [16], the implementation process has
been challenging. Low satisfaction scores, interoperabil-
ity problems, and lagging adoption in solo practices and
non-primary care practices are a few of the barriers
faced by EHRs [17]. Seven years after HITECH was
signed into law, efforts continue to overcome these
impediments, and without proper planning, precision
medicine could face issues similar to those experienced
by the EHR expansion.
Direct-to-consumer genetic tests
In reviewing the three principal components of precision
medicine (lifestyle, environment, and genomic informa-
tion), the most challenging piece may reside with patient
genetic information. Using genetic sequencing for
prediction and diagnosis has been in place for many
years, but in 2007, a new marketplace emerged where
customers were able to order their own genetic tests
online. Identified as Direct-to-Consumer (DTC), these
genetic tests help provide a window into what a preci-
sion medical model might look like in the very near
future. While the debate about the benefits and ethics of
these tests still continues [18–20], they have provided a
test bed to examine what works, and what areas need
improvement.
There are a variety of DTC tests available, and they
can cover a wide range of options, including tracking
ancestry and family history, looking at specific traits, or
searching for variants with known increased risk of
disease. The HapMap Project helped build the founda-
tion for carrying out genome-wide association studies
(GWAS) that searched for variants with disease associa-
tions. These studies uncovered genetic variations associ-
ated with more than 80 common polygenic diseases.
These GWASs focused on single-nucleotide polymor-
phisms (SNP), which are “sites in the genome sequence
of 3 billion nucleotide bases where individuals differ by a
single base” [21]. With approximately 10 million such
sites contained within the human genome, these SNPs
can serve as a shortcut to identify allelic variants of
identified genes. These shortcuts can then be linked to
increases or decreases in odds ratios (OR) for developing
various traits or diseases. This is an area where other
disciplines can help primary care physicians interpret
the results of DTC tests. With the reliance of some DTC
tests on Genome-wide Association Studies (GWAS) to
provide an estimate of increased or decreased risk for
particular conditions based on specific genetic variants,
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careful interpretation of the odds ratio and the effect
size is paramount to properly inform a patient about the
actual magnitude of the risk [22]. Knowledge of biostat-
istics concepts related to GWAS can be a valuable
resource for assessing the risks and the effect size associ-
ated with a variant.
Currently, DTC tests focus on SNP analysis. However,
future DTC tests will continue to grow in their complex-
ity as the traditional monogenic tests give way to more
advanced multigenic tests. When precision medicine
becomes standard practice, the expectation is that most
information will come from genomic tests. A critical
factor that will determine whether these tests will be
valuable in the clinical domain is their correct interpret-
ation by clinicians, and in particular by primary care
physicians. The American College of Medical Genetics
and Genomics reference this complexity when they
recommended that genetics experts should be available
for patient DTC genetic test result consultations [23].
There is evidence that primary care physicians feel ill-
equipped to answer questions about DTC tests brought
up by their patients. A 2012 study sent out mailers to
2,402 primary care and internal medicine providers in
North Carolina, of whom 382 responded. Only 38.7 %
(n = 148) were aware of DTC tests, and of those who
knew about the tests, only 15 % (n = 59) felt prepared to
answer questions about DTC results [24]. Indeed, even
prior to the arrival of DTC tests, most physicians were
unable to interpret even simple genetic tests [25]. This is
a trend that extends beyond the borders of the United
States. In a survey of five European countries (France,
Germany, The Netherlands, Sweden and the United
Kingdom), primary care physicians (n = 3,686, from a
sample frame of 139,579) were asked about their ability
to carry out basic medical genetic tasks. The findings
indicate that 44.2 % classified themselves as not
confident, 36.5 % somewhat confident, and only 19.3 %
were confident or very confident [26].
There are specialists who are trained to help interpret
these genetic test results, including molecular geneti-
cists, clinical geneticists, and genetic counselors. How-
ever, the number of them employed in the US healthcare
industry and globally is low compared to current and
future healthcare needs. As of 2015, there are 3,021
genetic counselors employed in the United States with
an additional 135 counselors practicing outside of the
US [27]. According to the American Board of Medical
Genetics and Genomics (ABMGG), as of July 2014 there
are only 1,286 certified clinical geneticists in the world.
A total 1,194 of the 1,286 are practicing in the United
States, which is only 0.18 % of all physicians in the US
[28]. There should be a caveat included with these
figures that at the time of data collection international
equivalent to the ABMGG or the US based National
Society of Genetic Counselors were unknown to us.
Thus, we were unable to arrive at sound figures for
employment of genetic counselors and clinical geneticist,
or their equivalent positions outside the US. Future work
may include reaching out to groups like the Australian
Society of Genetic Counsellors [29] or other international
societies to try and capture an improved global picture.
There are additional certified specialists recognized by
the ABMGG; however, the number of clinical geneticist
is more than double the closest alternative. Globally,
there are 618 certified clinical cytogenetists and 512
certified clinical molecular geneticists. There are 2,904
certificates recognized by the AMBGG across seven cat-
egories: clinical biochemical genetics, clinical biochem-
ical molecular genetics, clinical cytogenetics, clinical
genetics, clinical molecular genetics, medical biochem-
ical genetics, and PhD medical genetics. Only four of
these categories comprise specialists who can directly
work with patients, and thus only these are included in
our counts here: clinical genetics, clinical biochemical
genetics, clinical cytogenetics, and medical biochemical
genetics. With these combined numbers of these four
categories, there are 2,243 certified professional who are
able to work with patients and have expertise in genet-
ics. Going forward, they will be referred to as medical
geneticists. Combining this figure with the number of
genetic counselors yields only 5,264 specialists. It should
be noted that these figures are based off membership
and certifications from US-based organizations. These
numbers should increase with the inclusion of other
international certification boards. However, the relative
frequency of medical geneticist and counselors is
expected to remain small.
Increased market demand may lead to more genetic
counselors and medical geneticists being employed. Even
so, if this pattern continues, existing medical profes-
sionals may have to intervene to support the demand
until training and employment of specialists catches up.
Development of new clinical geneticists will continue to
grow slowly, since only 50 % of available clinical genetics
training slots are currently being filled at US medical
schools [30]. Demands for these positions are cited as
one reason for the low enrollment figures, but the
impact of monetary discrepancy between clinical gen-
etics and other specialties will also be explored later
in this paper.
Proposed actions
There are several factors that could slow or even prevent
precision medicine from becoming successfully inte-
grated into healthcare. As highlighted above, there is a
shortage of subject matter experts and documented low
confidence levels within the ranks of primary care physi-
cians on the topic of genetics. Failing to address these
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educational and staffing gaps will represent a major
stumbling block for precision medicine. Returning to the
four components identified as elements for a successful
integration of precision medicine (data, tools and sys-
tems, regulations, and people), we focus our suggestions
for avoiding these pitfalls on the people component.
In order to help streamline the success of the President’s
initiative, in addition to any efforts by other nations,
changes need to be implemented on two levels: (1) how
future physicians are trained, and (2) how current physi-
cians can successfully transition to using precision medi-
cine in the most efficient and effective way for their daily
practice. Increased training and employment of specialists
in genomics and the technology behind precision medi-
cine will support both future and current physicians
through this change. Therefore, we look at three categor-
ies where we feel change is needed: medical curriculum
reform, specialist training, and ongoing physician training.
Medical curriculum reform
Based on prior published position statements [31, 32],
medical students need additional exposure and training
in topics related to genetics and genomics. In order to
accomplish this, we suggest the following:
 Make genetics a core competency. Like anatomy,
genetics should be embedded in each level of
training in a medical student’s career (didactic
instruction, clinical rotations, and to a smaller
degree, specialization).
 Introduce biomedical and bioinformatics tools to
medical students. Computational methods will be an
integral component of precision medicine.
Therefore, students should be made aware of the
strengths and weakness of approaches like data
mining and GWAS, and be able to critically evaluate
findings derived from these types of study.
Introduction to standard statistical techniques
should also be included.
 Adjust entry requirements for medical schools.
Courses should include exposure to more advanced
genetics and genomics for incoming students.
Introductory genetics courses may not be sufficient
anymore.
 Offer dedicated training tracks in medical schools.
For example, Baylor College of Medicine offers a
Genetics Track Curriculum. Initiatives like this can
encourage more physicians to pursue one of the
medical genetic specialties.
 Integrate emerging research into graduate medical
education. Also known as medical residency
programs, training should be adjusted to apply
emerging research into clinical practice. Precision
medicine will create a closer link between research
and clinical practice, and students should be
prepared to take advantage of this.
Specialist training
Only pursuing enhanced training for future physicians
will not be adequate to meet the increasing demand for
trained professionals at all ranks. The number of subject
matter experts needs to increase too. This includes
genetic counselors, bioinformaticians, and biomedical
informatics specialists. In this context, bioinformatics
focuses on topics at the cellular and molecular level,
whereas biomedical informatics is concerned with the
public and patient level of healthcare. Medical geneti-
cists do not fall into the “specialist training” category,
since they have attended medical schools and thus serve
as more of a direct peer with other physicians. The role
of the specialists is complementary to that of the physi-
cians and will also be critical to ensure a successful
implementation of the precision medicine model. The
American Medical Informatics Association (AMIA)
position statements on biomedical informatics training
informs the following suggestions [33]:
 Promote informatics. Develop strategies to recruit,
retain, and educate students in the areas of
informatics and genetic counseling.
 Foundational support. Encourage foundations to
fund bioinformatics and biomedical informatics
doctoral programs and research.
 Encourage additional training in an informatics
area. Current medical professionals should pursue
education in nursing informatics, translational
informatics, biomedical informatics, or
bioinformatics.
 Establish new fellowships. In order to encourage
additional training by medical professionals, new
accredited informatics programs are needed,
following the lead of ACGME’s newly accredited
clinical informatics fellowship [34].
 Align the professions with precision medicine aims.
Informatics and genetic counseling curricula and
research should be adjusted to be in sync with
healthcare policies related to precision medicine.
 Voyage beyond genomics and DNA. Precision
medicine places a heavy emphasis on genomic data,
but in the near future, other assays will become just
as important. Future informatics professionals
should receive training in RNA-seq, epigenomics,
proteomics, metabolomics, and microbiome sequen-
cing. Understanding how to fuse and extract new
information from enriched data sets will be a critical
skill. Emerging techniques like splicing analysis for
splice site mutations [35] and seeking pathway
suppression/activation with pathway-specific gene
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sets [36] will require trained professionals to ensure
a proper fit within precision medicine. The work of
Chen R. et. al. in developing a personal omics
picture by connecting genomic, transcriptomic,
proteomic, metabolomic, and autoantibody profiles
[37] and the developing “networks medicine” model
[38] demonstrates the opportunity in this space.
On-going physician training
One advantage that precision medicine has over EHRs is
that it does not have to change the way every physician
operates. In the prior two categories, we emphasized the
need for ramping up the number of future specialists.
Current medical professionals will be relied upon as new
experts matriculate into the system. However, not every
physician currently practicing will need to participate, and
physician training can be voluntary. To accomplish the
goals of this category, we propose the following measures:
 Introduce new continuing medical education (CME)
courses. CMEs are a standard of training for
physicians to ensure medical knowledge remains
current. CMEs focused on precision medicine,
genomics, and the tools used in these fields should
be developed to match the changes implemented in
medical curriculum reform.
 Create precision medicine certification. Certification
status could be reached with given a number of
CME courses focused on precision medicine.
Organizations like the American Board of Medical
Genetics, American Medical Association, or other
national-level medical professional organizations
could offer these certificates.
 Proper staffing. Centers of care should be
encouraged to reach a certain percentage of staff
that are qualified to discuss precision medicine with
patients. This percentage can be reached through
genetic counselors, medical geneticists, or physicians
who have completed CMEs outlined above.
An important factor to consider besides the adequate
training of physicians and specialists is monetary com-
pensation. Key to the success of this revised education
model is to ensure that the salaries of medical geneticists
and specialists will be competitive enough to attract a
sufficient number of qualified individuals to the profes-
sion. The average salary for medical genetics is $158,597,
which falls well short of other specialties like emergency
medicine ($320,419) and pediatrics ($206,961). In com-
parison to some of the most sought-after specialties like
dermatology ($400,898) and orthopedic surgery ($535,688),
the discrepancy in pay becomes very apparent. In fact, med-
ical genetics remains one of the lowest paid specialties [39].
The mean annual wage for genetic counselors is $69,540
[40], but that may also not be high enough to attract a suffi-
cient number of professionals to this career.
Conclusions
The transition to a medical care model where providers
are afforded a higher degree of granularity in their treat-
ments and decisions is obviously desirable. Precision
medicine offers the potential to tie big data into the
equation for medicine. There is tremendous advantage
to incorporating big data analytics into healthcare, in-
cluding R&D acceleration, expanded genomic analysis,
and public health insights to name a few [41]. However,
big data is not a panacea, and even the best intentions
can lead to poor results if efforts in planning are inad-
equate. In this position paper, we highlighted some of
the challenges that EHR implementation has faced as a
path that precision medicine may follow if adequate
measures are not taken in time. EHRs adoption has been
bumpy at best due to multiple factors and poor phys-
ician satisfaction ranks highly among those adoption
barriers. Finding ways to ease the transition and hire
individuals tasked with ensuring clear communication
and the capabilities of precision medicine is possible way
to avoid the frustrations and disillusionment pitfalls
experienced with EHRs adoption.
There is currently a lack of experts ready to usher in
this paradigm shift, and current physicians appear to be
underequipped to take on the challenge alone. There is
still time to correct this, if actions are taken now. We
propose ways to address these deficiencies through
changes in medical curricula, specialist training, and
continuing education for current physicians. The prom-
ise of precision medicine is a desirable goal, and we are
convinced that through these actions it can arrive sooner
and be adequately positioned to have a positive impact
on human health at large.
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